Omeros Corp (FRA:3O8)
€ 3.774 -0.022 (-0.58%) Market Cap: 223.44 Mil Enterprise Value: 283.18 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 51/100

Omeros Corporation - Special Call Transcript

Dec 04, 2019 / 01:30PM GMT
Release Date Price: €13.2 (+2.96%)
Operator

Good morning, and welcome to today's conference for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for 1 week from today.

I'll turn the call over to Peter Cancelmo, General Counsel for Omeros.

Peter B. Cancelmo
Omeros Corporation - VP, General Counsel & Corporate Secretary

Good morning, and thank you for joining today to discuss data from our pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, which we will refer to today as stem cell TMA. These data were announced this morning via press release. The press release as well as the slide presentation accompanying this morning's call are available on our website at www.omeros.com.

I'd like to remind you that some of the statements that will be made on today's call will be forward-looking. These forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot